JP2022553940A5 - - Google Patents
Info
- Publication number
- JP2022553940A5 JP2022553940A5 JP2022522867A JP2022522867A JP2022553940A5 JP 2022553940 A5 JP2022553940 A5 JP 2022553940A5 JP 2022522867 A JP2022522867 A JP 2022522867A JP 2022522867 A JP2022522867 A JP 2022522867A JP 2022553940 A5 JP2022553940 A5 JP 2022553940A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- specific
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962916340P | 2019-10-17 | 2019-10-17 | |
| US62/916,340 | 2019-10-17 | ||
| PCT/US2020/055468 WO2021076545A1 (en) | 2019-10-17 | 2020-10-14 | Clec12a antibody fragment sequences and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022553940A JP2022553940A (ja) | 2022-12-27 |
| JP2022553940A5 true JP2022553940A5 (enExample) | 2023-10-23 |
| JP7796414B2 JP7796414B2 (ja) | 2026-01-09 |
Family
ID=75538859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522867A Active JP7796414B2 (ja) | 2019-10-17 | 2020-10-14 | Ｃｌｅｃ１２ａ抗体断片配列及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240117053A1 (enExample) |
| EP (1) | EP4045540A4 (enExample) |
| JP (1) | JP7796414B2 (enExample) |
| KR (1) | KR20220083760A (enExample) |
| CN (1) | CN114929745B (enExample) |
| AU (1) | AU2020368354B2 (enExample) |
| BR (1) | BR112022007219A2 (enExample) |
| CA (1) | CA3158111A1 (enExample) |
| IL (1) | IL292238A (enExample) |
| WO (1) | WO2021076545A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021268340A1 (en) * | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| CN115850476B (zh) * | 2022-08-09 | 2023-09-05 | 合源康华医药科技(北京)有限公司 | 一种cll1抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8536310B2 (en) * | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| EP2245153A4 (en) * | 2008-02-13 | 2011-06-22 | Dyax Corp | IMPROVED METHODS FOR PRODUCING SPECIFIC BINDING SAVINGS |
| JP2013508308A (ja) * | 2009-10-23 | 2013-03-07 | ガーバン インスティテュート オブ メディカル リサーチ | 修飾可変ドメイン分子、ならびにその産生および使用方法 |
| BR112015006824A2 (pt) * | 2012-09-27 | 2017-07-04 | Merus B V | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico |
| CN103467599B (zh) * | 2013-09-27 | 2015-06-17 | 中国农业科学院兰州兽医研究所 | 双峰驼源抗猪瘟兔化弱毒疫苗株e2抗原重链抗体vhh和用途 |
| EP3529268B1 (en) * | 2016-10-19 | 2025-02-26 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| MX2019012953A (es) * | 2017-05-02 | 2020-02-12 | Alligator Bioscience Ab | Anticuerpo biespecifico contra ox40 y ctla-4. |
| WO2019108065A1 (en) * | 2017-12-01 | 2019-06-06 | Merus N.V. | Use of bispecific antibody and il-15 for combination therapy |
| WO2019118918A1 (en) * | 2017-12-15 | 2019-06-20 | Aleta Biotherapeutics Inc. | Cd19 variants |
| US11951129B2 (en) * | 2018-01-09 | 2024-04-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compositions and methods for targeting CLEC12A-expressing cancers |
-
2020
- 2020-10-14 JP JP2022522867A patent/JP7796414B2/ja active Active
- 2020-10-14 EP EP20877981.9A patent/EP4045540A4/en active Pending
- 2020-10-14 AU AU2020368354A patent/AU2020368354B2/en active Active
- 2020-10-14 US US17/768,793 patent/US20240117053A1/en active Pending
- 2020-10-14 CN CN202080087719.7A patent/CN114929745B/zh active Active
- 2020-10-14 CA CA3158111A patent/CA3158111A1/en active Pending
- 2020-10-14 WO PCT/US2020/055468 patent/WO2021076545A1/en not_active Ceased
- 2020-10-14 KR KR1020227016032A patent/KR20220083760A/ko active Pending
- 2020-10-14 BR BR112022007219A patent/BR112022007219A2/pt unknown
-
2022
- 2022-04-13 IL IL292238A patent/IL292238A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105051067B (zh) | 用于引起细胞内化的cd20结合免疫毒素及其使用方法 | |
| US8865188B2 (en) | Methods and compositions for controlling assembly of viral proteins | |
| JP2008056679A5 (enExample) | ||
| JP2021524267A5 (enExample) | ||
| JP2021524275A5 (enExample) | ||
| JP2021524270A5 (enExample) | ||
| JP2022513420A5 (enExample) | ||
| JP2011501656A5 (enExample) | ||
| RU2017144606A (ru) | Иммуноцитокины на основе il-15 и il-15rа домена sushi | |
| CN114736291B (zh) | 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途 | |
| JP2023538422A5 (enExample) | ||
| JP2024520666A5 (enExample) | ||
| WO2011137687A1 (zh) | 一种抗癌胚抗原抗体及其应用 | |
| JP2020509737A5 (enExample) | ||
| WO2021082573A1 (zh) | 抗il-4r单域抗体及其应用 | |
| WO2021104414A1 (zh) | 一种细胞表面偶联抗体的方法及其应用 | |
| WO2021047386A1 (zh) | 靶向caix抗原的纳米抗体及其应用 | |
| JP2014500862A5 (enExample) | ||
| JP2024513559A5 (enExample) | ||
| JP2021521267A5 (enExample) | ||
| JP2024509332A5 (enExample) | ||
| JP2023529839A5 (enExample) | ||
| JP2009529915A5 (enExample) | ||
| CN1154659C (zh) | 新的抗艾滋病免疫毒素 | |
| CN109810195A (zh) | 一种鼠抗人cd123单克隆抗体及应用 |